Last reviewed · How we verify
NCT06274541
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
trial testing Somatic and Germline BRCA1/2 Testing in Serous Ovarian Tumor in 200 participants. Completed in 12 March 2026.
17 December 2025
Quick facts
| Lead sponsor | Cancer Trials Ireland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 22 March 2019 |
| Primary completion | 17 December 2025 |
| Estimated completion | 12 March 2026 |
| Sites | 5 locations across Ireland |
Drugs / interventions tested
- Somatic and Germline BRCA1/2 Testing
Conditions studied
- Serous Ovarian Tumor — all drugs for Serous Ovarian Tumor →
- Endometrioid Carcinoma Ovary — all drugs for Endometrioid Carcinoma Ovary →
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
- Primary Peritoneal Carcinoma — all drugs for Primary Peritoneal Carcinoma →
Sponsor
Cancer Trials Ireland — full company profile →
Who can join
18 and older, female only, with Serous Ovarian Tumor or Endometrioid Carcinoma Ovary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A pilot study to evaluate the feasibility of a NGS-based tumour BRCA1/2 mutation testing pathway initiated in the oncology clinic for patients with HGSEC, either at primary diagnosis or first relapse, whereby only patients with a positive germline BRCA1/2 mutation test will be referred to clinical genetics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06274541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Cancer Trials Ireland trials
Trials by the same sponsor.
- NCT07425002 — Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM) · NA · recruiting
- NCT06078813 — Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases · Phase 1, PHASE2 · recruiting
- NCT05710666 — Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast · Phase 2 · active not recruiting
- NCT05518110 — PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Canc · Phase 2 · terminated
- NCT05123131 — Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06274541 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer Trials Ireland
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06274541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing